Astellas Pharma China, Inc.

🇨🇳China

Country: 🇨🇳China

Ownership: Subsidiary

Established: 1994-10-14

Employees: -

Market Cap: -

Website: https://www.astellas.com.cn

Clinical Trials

A Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients

Phase 4

Completed

Conditions: Liver Transplantation
Kidney Transplantation

Interventions: Drug: Tacrolimus granules

First Posted Date: 2021-12-10

Last Posted Date: 2024-12-02

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 56

Registration Number: NCT05153915

Locations: 🇨🇳
Site CN86001, Guangzhou, China
🇨🇳
Site CN86003, Beijing, China
🇨🇳
Site CN86006, Changsha, China

and more 4 locations

A Study of Modigraf® (Tacrolimus Granules) to Evaluate the Pharmacokinetics and Long-term Safety and Efficacy in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients

Phase 4

Completed

Conditions: Kidney Transplantation
Liver Transplantation

Interventions: Drug: Tacrolimus granules

First Posted Date: 2021-12-10

Last Posted Date: 2024-12-02

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 55

Registration Number: NCT05152628

Locations: 🇨🇳
Site CN86001, Shanghai, China
🇨🇳
Site CN86003, Beijing, China
🇨🇳
Site CN86002, Guangzhou, China

and more 1 locations

A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy

Phase 2

Active, not recruiting

Conditions: Metastatic Urothelial Cancer

Interventions: Drug: Enfortumab vedotin

First Posted Date: 2021-08-09

Last Posted Date: 2024-12-16

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 40

Registration Number: NCT04995419

Locations: 🇨🇳
Site CN86002, Guangzhou, China
🇨🇳
Site CN86004, Shanghai, China
🇨🇳
Site CN86001, Beijing, China

and more 4 locations

A Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: fezolinetant

First Posted Date: 2021-03-11

Last Posted Date: 2024-10-26

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 16

Registration Number: NCT04793204

Locations: 🇨🇳
Site CN86001, Bei'jing, China

A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder

Phase 4

Completed

Conditions: Overactive Bladder (OAB)
Urge Incontinence

Interventions: Drug: mirabegron

First Posted Date: 2020-09-24

Last Posted Date: 2024-11-15

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 249

Registration Number: NCT04562090

Locations: 🇨🇳
Site CN86014, Beijing, China
🇨🇳
Site CN86010, Chengdu, China
🇨🇳
Site CN86009, Guangzhou, China

and more 12 locations

A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants

Phase 4

Completed

Conditions: Pharmacokinetics of Mirabegron
Healthy Chinese Subjects
Food Effect

Interventions: Drug: mirabegron

First Posted Date: 2020-08-06

Last Posted Date: 2024-11-11

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 24

Registration Number: NCT04501640

Locations: 🇨🇳
Site CN86001, Shanghai, China

A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause

Phase 3

Completed

Conditions: Hot Flashes

Interventions: Drug: Fezolinetant

First Posted Date: 2020-06-30

Last Posted Date: 2024-10-26

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 150

Registration Number: NCT04451226

Locations: 🇨🇳
Site CN86012, Hangzhou, China
🇨🇳
Site CN86005, Hunan, China
🇨🇳
Site CN86037, Liuzhou, China

and more 26 locations

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause

Phase 3

Completed

Conditions: Hot Flashes

Interventions: Drug: Fezolinetant
Drug: Placebo

First Posted Date: 2020-01-21

Last Posted Date: 2024-10-26

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 302

Registration Number: NCT04234204

Locations: 🇨🇳
Site CN86006, Guangzhou, China
🇨🇳
Site CN86025, Hangzhou, China
🇨🇳
Site CN86021, Shenzhen, China

and more 45 locations

A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: peficitinib

First Posted Date: 2019-10-29

Last Posted Date: 2024-10-21

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 36

Registration Number: NCT04143477

Locations: 🇨🇳
Site CN86001, Beijing, China

A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Phase 1

Completed

Conditions: Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Interventions: Drug: zolbetuximab

First Posted Date: 2019-09-12

Last Posted Date: 2024-11-20

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 12

Registration Number: NCT04086758

Locations: 🇨🇳
Site CN86001, Guangzhou, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy